GALEN PHARM 210 EXAM 2026/2027 | 100% Correct Answers
with Complete Solutions | Pharmacological Principles, Drug
Classifications, Medication Administration | Pass Guaranteed
- A+ Graded
Unit 1: Pharmacokinetics & Pharmacodynamics (12 Questions)
Q1: A 68-year-old male patient with liver cirrhosis is prescribed a medication that
undergoes extensive first-pass metabolism. Which pharmacokinetic change should the
nurse anticipate?
A. Decreased bioavailability of the medication
B. Increased plasma concentration of the medication
C. Rapid elimination of the medication through the kidneys
D. Decreased volume of distribution for the medication
Correct Answer: B
Rationale: First-pass metabolism occurs in the liver; impaired hepatic function reduces
metabolism, leading to increased bioavailability and plasma concentration. Option A is
incorrect because bioavailability increases, not decreases, when first-pass metabolism
is impaired. Option C is unrelated—renal elimination is separate from hepatic
metabolism. Option D is incorrect—volume of distribution is typically increased in liver
disease due to decreased protein binding and altered body composition.
,Q2: A nurse is administering a drug with a half-life of 8 hours. How long will it take to
reach approximately 94% of steady-state concentration?
A. 8 hours
B. 16 hours
C. 24 hours
D. 32 hours
Correct Answer: D
Rationale: Steady state is reached in approximately 4-5 half-lives; 4 half-lives = 32 hours
(93.75% of steady state). Option A represents one half-life (50% elimination or
accumulation). Option B represents two half-lives (75%). Option C represents three
half-lives (87.5%).
Q3: A patient is receiving a drug that acts as a non-selective beta-blocker. Which
pharmacodynamic effect is expected?
A. Bronchodilation and increased heart rate
B. Bronchoconstriction and decreased heart rate
C. Vasodilation and increased cardiac output
D. Glycogenolysis and hyperglycemia
Correct Answer: B
Rationale: Non-selective beta-blockers block beta-1 (cardiac: decreased HR,
contractility) and beta-2 (pulmonary: bronchoconstriction, no bronchodilation). Option A
,describes beta-agonist effects. Option C describes vasodilation (not beta-blocker
effect). Option D describes beta-2 mediated glycogenolysis which is blocked, not
enhanced.
Q4: A nurse is caring for a patient receiving a drug with a narrow therapeutic index.
Which nursing action is the priority?
A. Administering the drug with food to enhance absorption
B. Monitoring plasma drug levels and assessing for toxicity
C. Teaching the patient to double the dose if a dose is missed
D. Encouraging grapefruit juice to increase bioavailability
Correct Answer: B
Rationale: Narrow therapeutic index drugs (digoxin, lithium, phenytoin, warfarin) have
small safety margin between therapeutic and toxic levels; therapeutic drug monitoring is
essential. Option A may be appropriate for some drugs but not the priority. Option C is
dangerous—dose doubling increases toxicity risk. Option D is dangerous—grapefruit
juice affects metabolism of many narrow index drugs.
Q5: A patient is prescribed a prodrug that requires hepatic conversion to its active form.
The patient has severe hepatic impairment. Which outcome is expected?
A. Enhanced therapeutic effect due to accumulation
B. Reduced therapeutic effect due to impaired activation
C. Increased risk of adverse effects from active metabolites
, D. No change in pharmacological response
Correct Answer: B
Rationale: Prodrugs (codeine, enalapril, prednisone) require hepatic activation; impaired
liver function reduces conversion to active drug, decreasing therapeutic effect. Option A
is opposite of expected effect. Option C would occur with drugs metabolized to toxic
metabolites. Option D is incorrect—hepatic impairment significantly affects prodrugs.
Q6: A nurse is administering a highly protein-bound drug to a patient with
hypoalbuminemia. Which effect is anticipated?
A. Decreased free drug concentration and reduced effect
B. Increased free drug concentration and potential toxicity
C. No change in drug distribution or effect
D. Decreased volume of distribution and prolonged action
Correct Answer: B
Rationale: Reduced albumin decreases binding sites, increasing free (unbound, active)
drug concentration, enhancing effect and toxicity risk (e.g., phenytoin, warfarin). Option
A is opposite mechanism. Option C is incorrect—protein binding significantly affects
pharmacokinetics. Option D describes decreased volume of distribution which is not the
primary concern.
Q7: A patient is receiving a drug that is a competitive antagonist at the receptor site.
Which characteristic describes its mechanism?
A. Binds irreversibly and reduces receptor number
with Complete Solutions | Pharmacological Principles, Drug
Classifications, Medication Administration | Pass Guaranteed
- A+ Graded
Unit 1: Pharmacokinetics & Pharmacodynamics (12 Questions)
Q1: A 68-year-old male patient with liver cirrhosis is prescribed a medication that
undergoes extensive first-pass metabolism. Which pharmacokinetic change should the
nurse anticipate?
A. Decreased bioavailability of the medication
B. Increased plasma concentration of the medication
C. Rapid elimination of the medication through the kidneys
D. Decreased volume of distribution for the medication
Correct Answer: B
Rationale: First-pass metabolism occurs in the liver; impaired hepatic function reduces
metabolism, leading to increased bioavailability and plasma concentration. Option A is
incorrect because bioavailability increases, not decreases, when first-pass metabolism
is impaired. Option C is unrelated—renal elimination is separate from hepatic
metabolism. Option D is incorrect—volume of distribution is typically increased in liver
disease due to decreased protein binding and altered body composition.
,Q2: A nurse is administering a drug with a half-life of 8 hours. How long will it take to
reach approximately 94% of steady-state concentration?
A. 8 hours
B. 16 hours
C. 24 hours
D. 32 hours
Correct Answer: D
Rationale: Steady state is reached in approximately 4-5 half-lives; 4 half-lives = 32 hours
(93.75% of steady state). Option A represents one half-life (50% elimination or
accumulation). Option B represents two half-lives (75%). Option C represents three
half-lives (87.5%).
Q3: A patient is receiving a drug that acts as a non-selective beta-blocker. Which
pharmacodynamic effect is expected?
A. Bronchodilation and increased heart rate
B. Bronchoconstriction and decreased heart rate
C. Vasodilation and increased cardiac output
D. Glycogenolysis and hyperglycemia
Correct Answer: B
Rationale: Non-selective beta-blockers block beta-1 (cardiac: decreased HR,
contractility) and beta-2 (pulmonary: bronchoconstriction, no bronchodilation). Option A
,describes beta-agonist effects. Option C describes vasodilation (not beta-blocker
effect). Option D describes beta-2 mediated glycogenolysis which is blocked, not
enhanced.
Q4: A nurse is caring for a patient receiving a drug with a narrow therapeutic index.
Which nursing action is the priority?
A. Administering the drug with food to enhance absorption
B. Monitoring plasma drug levels and assessing for toxicity
C. Teaching the patient to double the dose if a dose is missed
D. Encouraging grapefruit juice to increase bioavailability
Correct Answer: B
Rationale: Narrow therapeutic index drugs (digoxin, lithium, phenytoin, warfarin) have
small safety margin between therapeutic and toxic levels; therapeutic drug monitoring is
essential. Option A may be appropriate for some drugs but not the priority. Option C is
dangerous—dose doubling increases toxicity risk. Option D is dangerous—grapefruit
juice affects metabolism of many narrow index drugs.
Q5: A patient is prescribed a prodrug that requires hepatic conversion to its active form.
The patient has severe hepatic impairment. Which outcome is expected?
A. Enhanced therapeutic effect due to accumulation
B. Reduced therapeutic effect due to impaired activation
C. Increased risk of adverse effects from active metabolites
, D. No change in pharmacological response
Correct Answer: B
Rationale: Prodrugs (codeine, enalapril, prednisone) require hepatic activation; impaired
liver function reduces conversion to active drug, decreasing therapeutic effect. Option A
is opposite of expected effect. Option C would occur with drugs metabolized to toxic
metabolites. Option D is incorrect—hepatic impairment significantly affects prodrugs.
Q6: A nurse is administering a highly protein-bound drug to a patient with
hypoalbuminemia. Which effect is anticipated?
A. Decreased free drug concentration and reduced effect
B. Increased free drug concentration and potential toxicity
C. No change in drug distribution or effect
D. Decreased volume of distribution and prolonged action
Correct Answer: B
Rationale: Reduced albumin decreases binding sites, increasing free (unbound, active)
drug concentration, enhancing effect and toxicity risk (e.g., phenytoin, warfarin). Option
A is opposite mechanism. Option C is incorrect—protein binding significantly affects
pharmacokinetics. Option D describes decreased volume of distribution which is not the
primary concern.
Q7: A patient is receiving a drug that is a competitive antagonist at the receptor site.
Which characteristic describes its mechanism?
A. Binds irreversibly and reduces receptor number
